Can you stay on Mounjaro forever — and what does the evidence say?

Why the question of stopping matters so much

If you are weighing up long-term Mounjaro use, you are probably doing so because the medicine is working and you are wondering whether that means you will need to stay on it forever. That is a fair question, and an honest answer is yes, for many people, the answer looks a lot like other chronic conditions such as blood pressure or cholesterol, where medicine continues because the condition continues.

Tirzepatide reduces appetite and slows gastric emptying by activating two gut-hormone receptors. When you stop taking it, those receptors return to their pre-treatment baseline. The hunger signals that were quietened start up again. Clinical trial extension work has shown that participants who discontinued regained a significant portion of lost weight within a year. The NHS patient information on tirzepatide makes clear that treatment is intended to run alongside lifestyle changes, and it does not set an upper time limit.

That does not mean you are locked in forever. It means the question is worth discussing with a prescriber before you start, not as a reason to avoid treatment, but so your expectations are grounded. Some people choose to continue; others reach a stable lower weight and, with clinical guidance, step down carefully. Both paths exist.

What the licence and NICE guidance actually say about duration

Mounjaro's UK licence places no ceiling on how long treatment can run, provided it remains clinically appropriate. NICE's appraisal of tirzepatide (TA1026, updated September 2025) sets eligibility criteria around BMI and comorbidities, it does not impose a maximum duration. This is a notable difference from the NHS recommendation for semaglutide (Wegovy), which carries a two-year limit on NHS use and requires a specialist service.

NICE does include a review trigger: if someone has not lost at least five percent of their body weight after six months on the highest tolerated dose, continuing treatment should be reconsidered. That is a clinical exit point, not a time exit point. For people who respond well, there is no guidance that says treatment should stop once a target weight is reached.

Private prescribing follows the licensed indication rather than NHS commissioning conditions. If you are wondering about the practical reality of long-term treatment, the short version is that eligibility is reassessed at each repeat, the medicine stays appropriate as long as the clinical picture supports it.

The weight-regain reality: what the evidence shows

This is the part that surprises people most. In SURMOUNT-1 (a trial of over 2,500 adults with obesity) participants who completed 72 weeks and then stopped treatment regained most of their lost weight within the following year. Researchers published these findings in the New England Journal of Medicine. The implication is not that Mounjaro failed; it is that obesity is a chronic biological condition, and treating it with a medicine that works only while you take it is the same logic as any other chronic-disease management.

Some people manage to maintain weight after stopping by sustaining the dietary and activity habits built during treatment. That is real and worth pursuing. But the research suggests it is the exception rather than the rule at a population level. Understanding this upfront helps you plan, and it is one reason our clinical team treats aftercare as part of the prescription, not a bolt-on. You can read more about the question of lifelong treatment in detail, including what stepping down looks like in practice.

Making the decision with your prescriber

There is no single right answer to whether you should stay on Mounjaro indefinitely. The right answer depends on your BMI, your comorbidities, how you have responded to treatment, whether you have conditions that improve with weight loss, and what your own priorities are. A prescriber can map that against your current health in a way that a search result cannot.

What a prescriber cannot do is make that decision for you without a proper assessment. At nume, every repeat goes through a clinical review, there is no automatic renewal. If you want to explore what treatment could look like for you, including what duration might be appropriate, the place to start is a free consultation where a GPhC-registered prescriber reviews your answers the same day. If you are also thinking about the financial side of continuing treatment, our Mounjaro pricing page sets out what is included in one transparent price. More background on tirzepatide as a medicine and weight-loss treatment options more broadly is available if you want to read further before deciding.